KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for Royalty Pharma (RPRX) over the last 6 years, with Q4 2025 value amounting to $0.5.

  • Royalty Pharma's EPS (Weighted Average and Diluted) rose 638.3% to $0.5 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.79, marking a year-over-year decrease of 677.08%. This contributed to the annual value of $1.78 for FY2025, which is 680.63% down from last year.
  • Royalty Pharma's EPS (Weighted Average and Diluted) amounted to $0.5 in Q4 2025, which was up 638.3% from $0.67 recorded in Q3 2025.
  • Royalty Pharma's 5-year EPS (Weighted Average and Diluted) high stood at $1.21 for Q3 2024, and its period low was -$1.04 during Q4 2022.
  • Its 5-year average for EPS (Weighted Average and Diluted) is $0.4, with a median of $0.4 in 2024.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 90377.5% in 2022, then surged by 540000.0% in 2025.
  • Over the past 5 years, Royalty Pharma's EPS (Weighted Average and Diluted) (Quarter) stood at $0.13 in 2021, then tumbled by 903.77% to -$1.04 in 2022, then surged by 205.77% to $1.1 in 2023, then tumbled by 57.27% to $0.47 in 2024, then grew by 6.38% to $0.5 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at $0.5 for Q4 2025, versus $0.67 for Q3 2025 and $0.07 for Q2 2025.